adenine has been researched along with lenalidomide in 34 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (2.94) | 29.6817 |
2010's | 27 (79.41) | 24.3611 |
2020's | 6 (17.65) | 2.80 |
Authors | Studies |
---|---|
Jain, P | 1 |
Balasubramanian, S; Buggy, JJ; Ceribelli, M; Emre, NC; Ferrer, M; Guha, R; Kohlhammer, H; Mathews, LA; Platig, J; Powell, J; Shaffer, AL; Shinn, P; Staudt, LM; Thomas, C; Waldmann, TA; Wright, G; Xiao, W; Xu, W; Yang, Y; Young, RM; Zhang, M; Zhao, H | 1 |
Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
Blum, KA; Maddocks, K | 1 |
Yamamoto, K | 1 |
Abdul-Hay, M; Desai, AV; El-Bakkar, H | 1 |
Govindarajulu, B; Rangasamy, M; Thappali, S; Vakkalanka, S; Veeraraghavan, S; Viswanadha, S | 1 |
Gong, J; Mita, M; Rimel, B; Sachdev, E | 1 |
Robak, T; Smolewski, P; Witkowska, M | 1 |
Cheah, CY; Seymour, JF; Wang, ML | 1 |
Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S | 1 |
Chen, L; de Miranda, NF; Dlugosz-Danecka, M; Galazka, K; Jurczak, W; Machaczka, M; Mansouri, L; Morin, RD; Pan-Hammarström, Q; Peng, R; Rosenquist, R; Sander, B; Wasik, AM; Wu, C; Zhang, H | 1 |
Bartlett, NL; Blum, KA; Cheson, BD; Czuczman, M; Davids, MS; Jung, SH; Leonard, JP; Levine, E; Lewis, LD; Martin, P; Park, SI; Pitcher, B; Smith, SE; Smith, SM; Ujjani, CS | 1 |
Chen, W; Lee, HJ; Nomie, K; Oriabure, O; Romaguera, J; Srour, SA; Wang, ML; Ye, H | 1 |
Apollonio, B; Chiu, H; Chopra, R; Couto, S; Flynt, E; Gandhi, AK; Hagner, PR; Ortiz, M; Ramsay, AG; Thakurta, A; Trotter, M; Waldman, MF; Wang, M | 1 |
Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M | 1 |
Thieblemont, C | 1 |
Dahl, C; Eskelund, CW; Geisler, CH; Grønbæk, K; Hutchings, M; Jerkeman, M; Kolstad, A; Kuitunen, H; Laurell, A; Niemann, CU; Pedersen, LB; Räty, R; Toldbod, H; Wader, KF | 1 |
Cheson, BD; Khan, N; Ramzi, P; Skarbnik, A; Trivedi, N; Ujjani, C; Wang, H | 1 |
Illerhaus, G; Kasenda, B; Schorb, E | 1 |
Till, BG | 1 |
Anwer, F; Durer, C; Durer, S; Faridi, W; Fraz, MA; Ijaz, A; Khan, AY; Kumar, A; Malik, SU; Nasar, A; Qureshi, A; Tariq, MJ; Usman, M | 1 |
Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
Alijanazreh, H; Gentile, M; Hamamreh, Y; Hindiyeh, M; Kashkeesh, A; Morabito, F; Morabito, L; Recchia, AG; Sabatleen, A; Skafi, M | 1 |
Beaupre, DM; Dang, NH; Delioukina, M; Ghosh, N; Goy, A; Kingsley, E; Knapp, M; Morgan, DS; Munoz, J; Neuenburg, JK; Ping, J; Ramchandren, R; Ruan, J | 1 |
Westin, J | 1 |
Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J | 1 |
Abreu, MM; Gouvea, J; Jewett, A; Ko, MW; Maharaj, D; Srinivasan, G | 1 |
Beaupre, D; Chhabra, S; de Vos, S; Huang, DW; Kimball, AS; Kwei, K; Neuenburg, JK; Phillips, T; Ping, J; Popplewell, L; Staudt, LM; Wilson, WH; Wright, G | 1 |
Steck, AJ | 1 |
Ghosh, N; Hu, B; Jacobs, R; Levine, J; Moore, DC; Moyo, TK; Park, SI; Smith, ET; Soni, AC | 1 |
Cheng, S; Fang, H; Huang, HY; Jiang, L; Li, JF; Ouyang, BS; Qian, Y; Shi, ZY; Wang, L; Xu, PP; Yi, HM; Zhao, WL; Zhu, Y | 1 |
Fisch, SC; Jonas, BA; Qi, L; Tuscano, JM | 1 |
15 review(s) available for adenine and lenalidomide
Article | Year |
---|---|
Lenalidomide-induced acute liver failure.
Topics: Adenine; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Hepatitis B, Chronic; Humans; Lenalidomide; Liver Failure, Acute; Male; Myelodysplastic Syndromes; Organophosphonates; Thalidomide | 2009 |
Ibrutinib in B-cell Lymphomas.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Thalidomide; Treatment Outcome | 2014 |
[Standard of care and new drugs for diffuse large B-cell lymphoma].
Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Discovery; Epigenesis, Genetic; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Molecular Targeted Therapy; Piperidines; Prednisolone; Prednisone; Pyrazoles; Pyrimidines; Radiotherapy, Adjuvant; Rituximab; Thalidomide; Vincristine; Vindesine | 2014 |
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide | 2015 |
Treatment options for mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Piperidines; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Rituximab; Thalidomide | 2015 |
Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cytarabine; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Staging; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Risk Factors; Rituximab; Thalidomide; Transplantation, Autologous | 2016 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia | 2016 |
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Splenic Neoplasms; Survival Rate; Thalidomide | 2017 |
Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nivolumab; Piperidines; Pyrazoles; Pyrimidines; Recurrence | 2018 |
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Everolimus; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine; Young Adult | 2018 |
Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients.
Topics: Adenine; Aged; Aged, 80 and over; Anthracyclines; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Female; Frail Elderly; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine | 2018 |
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
Lenalidomide for the treatment of mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Piperidines; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome | 2019 |
Anti-MAG neuropathy: From biology to clinical management.
Topics: Adenine; Animals; Autoantibodies; Autoantigens; B-Lymphocyte Subsets; CD57 Antigens; Demyelinating Autoimmune Diseases, CNS; Epitopes; Gait Disorders, Neurologic; Humans; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Mammals; Mice; Molecular Mimicry; Myelin Sheath; Myelin-Associated Glycoprotein; Nerve Fibers, Myelinated; Nervous System Autoimmune Disease, Experimental; Paraproteinemias; Paraproteins; Piperidines; Plasma Exchange; Polyradiculoneuropathy; Ranvier's Nodes; Rats; Rituximab | 2021 |
8 trial(s) available for adenine and lenalidomide
Article | Year |
---|---|
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Survival Rate; Thalidomide | 2016 |
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Coculture Techniques; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphocyte Count; Lymphoma, Mantle-Cell; Mutation; Peptide Hydrolases; Piperidines; Pyrazoles; Pyrimidines; Thalidomide; Treatment Outcome; Tumor Cells, Cultured; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2017 |
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Mutation; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Retreatment; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome | 2018 |
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Progression-Free Survival; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Rituximab; Salvage Therapy | 2018 |
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome | 2019 |
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Piperidines; Prednisone; Treatment Outcome; Vincristine | 2021 |
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Frail Elderly; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Piperidines; Rituximab | 2022 |
Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy.
Topics: Adenine; Chromosome Deletion; Humans; Lenalidomide; Piperidines | 2022 |
11 other study(ies) available for adenine and lenalidomide
Article | Year |
---|---|
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; DNA-Binding Proteins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Interferon Regulatory Factors; Interferon-beta; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Peptide Hydrolases; Piperidines; Pyrazoles; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thalidomide; Transcription Factors; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2013 |
Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study.
Topics: Adenine; Animals; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Lenalidomide; Liquid-Liquid Extraction; Male; Piperidines; Plasma; Pyrazoles; Pyrimidines; Rats; Rats, Wistar; Reproducibility of Results; Tandem Mass Spectrometry; Thalidomide; Tolbutamide | 2015 |
Adnectin-targeted inhibitors: rationale and results.
Topics: Adenine; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fibronectins; Humans; Lenalidomide; Molecular Targeted Therapy; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pyrazoles; Pyrimidines; Thalidomide; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
Topics: Adenine; CARD Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Genetic Heterogeneity; Guanylate Cyclase; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Mutation; NF-kappa B; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Signal Transduction; Thalidomide; Transfection | 2016 |
Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2018 |
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Topics: Adenine; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperidines; Pyrazoles; Pyrimidines; Recurrence; Thalidomide | 2017 |
Ibrutinib and lenalidomide: when 1+1 = >2.
Topics: Adenine; B-Lymphocytes; Lenalidomide; Piperidines; Pyrazoles; Pyrimidines; Rituximab | 2019 |
Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV- Unmutated Chronic Lymphocytic Leukemia.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Immunologic Factors; Immunotherapy; Interleukin-2; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Piperidines; Precision Medicine; Prognosis; Remission Induction; Sulfonamides | 2020 |
Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Leg; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperidines; Rituximab | 2022 |